Amazing pleiotropic effects of azithromycin

Lies Lahousse

Source: Breathe, 14 (4) 336; 10.1183/20734735.025118
Journal Issue: December
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Lies Lahousse. Amazing pleiotropic effects of azithromycin. Breathe, 14 (4) 336; 10.1183/20734735.025118

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001


Anti-inflammatory properties of nimesulide and clarithromycin: a comparative study during the therapy of bronchial sepsis involving P.aeruginosa
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002

Adverse effects of moxifloxacin during tuberculosis treatment
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012

The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug)
Source: Eur Respir J 2001; 18: Suppl. 33, 543s
Year: 2001

The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004

TNFα-induced glucocorticoid resistance: Effect of steroidal and non-steroidal GR agonists, formoterol and inhibition of inflammatory signalling
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012

Macrolides as anti-inflammatory agents in CAP
Source: Eur Respir Monogr 2014; 63: 243-255
Year: 2014


Mechanisms of systemic side effects of inhaled steroids
Source: Eur Respir J 2004; 24: Suppl. 48, 347s
Year: 2004

Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019

Synergistic action of the anticholinergic r,r-glycopyrrolate with glucocorticoids and PDE4-inhibitors
Source: Eur Respir J 2005; 26: Suppl. 49, 217s
Year: 2005

Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD
Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018
Year: 2019



Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 147s
Year: 2001

Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009

Pharmacodynamic effects of nebulised bronchodilator combinations
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020


Is high-dose glucocorticoid beneficial in COVID-19?
Source: Eur Respir J, 57 (4) 2100065; 10.1183/13993003.00065-2021
Year: 2021



An anti-inflammatory effect of azithromycin in cystic fibrosis
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010

Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008


Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


New researches on teratogenic and embryogenotoxic effects of tiotropium
Source: Eur Respir J 2005; 26: Suppl. 49, 121s
Year: 2005

Novel anti-inflammatory agents
Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Year: 2009